Document Type

Article

Publication Date

12-10-2021

Publication Title

Hematology Am Soc Hematol Educ Program

Abstract

Early in the pandemic, COVID-19-related increases in rates of venous and arterial thromboembolism were seen. Many observational studies suggested a benefit of prophylactic anticoagulation for hospitalized patients using various dosing strategies. Randomized trials were initiated to compare the efficacy of these different options in acutely ill and critically ill inpatients as the concept of immune-mediated inflammatory microthrombosis emerged. We present a case-based review of how we approach thromboembolic prophylaxis in COVID-19 and briefly discuss the epidemiology, the pathophysiology, and the rare occurrence of vaccine-induced thrombotic thrombocytopenia.

Medical Subject Headings

Anticoagulants; Blood Coagulation; COVID-19; COVID-19 Vaccines; Critical Illness; Humans; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Risk Factors; Thrombosis

PubMed ID

34889411

Volume

2021

Issue

1

First Page

621

Last Page

627

Available for download on Friday, June 10, 2022

Share

COinS